Critical evaluation of modified-release formulation containing silybum marianum extract for oral application

Dávid Sinka, Alexandra Hagymási, Pálma Fehér, Zoltán Ujhelyi, Miklós Vecsernyés, Ferenc Fenyvesi, Judit Váradi, Gábor Vasvári, Tünde Jurca, Sebastian Nemeth, Daniela Elena Popa, Ildikó Bácskay

Research output: Article

Abstract

Silymarin is the extract of active ingredients of the plant Silybum marianum. It is used in medicine for curing or preventing liver and gall diseases for thousands of years. Silymarin has a low solubility and permeability, belongs to BCS class IV. Its current pharmacotherapy means conventional dosage forms such as capsules, but it results in low bioavailability. Our main goals through the research were to formulate matrix tablets with silymarin as active ingredient. We used different carbopols as matrix-forming polymers. The complexation of silymarin with different β-cyclodextrins was intended to increase the solubility of the active ingredient. By achieving sustained release, our aim was to offer a better alternative than the conventional unsuccessful oral therapy. Comparing the results of our research, we could select the carbopol-cyclodextrin combination with the optimal drug release from the twenty different compounds. With these compositions, more than 85% of the silymarin was dissolved. The cytocompatibility of our product was proven, and the technology provided much better bioavailability than the conventional silymarin therapy.

Original languageEnglish
Pages (from-to)806-819
Number of pages14
JournalFarmacia
Volume67
Issue number5
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Milk Thistle
Silymarin
Cyclodextrins
Solubility
Biological Availability
Dosage Forms
Research
Tablets
Capsules
Liver Diseases
Permeability
Polymers
Medicine
Technology
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Critical evaluation of modified-release formulation containing silybum marianum extract for oral application. / Sinka, Dávid; Hagymási, Alexandra; Fehér, Pálma; Ujhelyi, Zoltán; Vecsernyés, Miklós; Fenyvesi, Ferenc; Váradi, Judit; Vasvári, Gábor; Jurca, Tünde; Nemeth, Sebastian; Popa, Daniela Elena; Bácskay, Ildikó.

In: Farmacia, Vol. 67, No. 5, 01.01.2019, p. 806-819.

Research output: Article

Sinka, D, Hagymási, A, Fehér, P, Ujhelyi, Z, Vecsernyés, M, Fenyvesi, F, Váradi, J, Vasvári, G, Jurca, T, Nemeth, S, Popa, DE & Bácskay, I 2019, 'Critical evaluation of modified-release formulation containing silybum marianum extract for oral application', Farmacia, vol. 67, no. 5, pp. 806-819. https://doi.org/10.31925/farmacia.2019.5.9
Sinka, Dávid ; Hagymási, Alexandra ; Fehér, Pálma ; Ujhelyi, Zoltán ; Vecsernyés, Miklós ; Fenyvesi, Ferenc ; Váradi, Judit ; Vasvári, Gábor ; Jurca, Tünde ; Nemeth, Sebastian ; Popa, Daniela Elena ; Bácskay, Ildikó. / Critical evaluation of modified-release formulation containing silybum marianum extract for oral application. In: Farmacia. 2019 ; Vol. 67, No. 5. pp. 806-819.
@article{26f529da3fb841e9822791ddbc61f6d7,
title = "Critical evaluation of modified-release formulation containing silybum marianum extract for oral application",
abstract = "Silymarin is the extract of active ingredients of the plant Silybum marianum. It is used in medicine for curing or preventing liver and gall diseases for thousands of years. Silymarin has a low solubility and permeability, belongs to BCS class IV. Its current pharmacotherapy means conventional dosage forms such as capsules, but it results in low bioavailability. Our main goals through the research were to formulate matrix tablets with silymarin as active ingredient. We used different carbopols as matrix-forming polymers. The complexation of silymarin with different β-cyclodextrins was intended to increase the solubility of the active ingredient. By achieving sustained release, our aim was to offer a better alternative than the conventional unsuccessful oral therapy. Comparing the results of our research, we could select the carbopol-cyclodextrin combination with the optimal drug release from the twenty different compounds. With these compositions, more than 85{\%} of the silymarin was dissolved. The cytocompatibility of our product was proven, and the technology provided much better bioavailability than the conventional silymarin therapy.",
keywords = "Caco-2 cells, Cyclodextrin, HPBCD, Modified-release, Silybum marianum",
author = "D{\'a}vid Sinka and Alexandra Hagym{\'a}si and P{\'a}lma Feh{\'e}r and Zolt{\'a}n Ujhelyi and Mikl{\'o}s Vecserny{\'e}s and Ferenc Fenyvesi and Judit V{\'a}radi and G{\'a}bor Vasv{\'a}ri and T{\"u}nde Jurca and Sebastian Nemeth and Popa, {Daniela Elena} and Ildik{\'o} B{\'a}cskay",
year = "2019",
month = "1",
day = "1",
doi = "10.31925/farmacia.2019.5.9",
language = "English",
volume = "67",
pages = "806--819",
journal = "Farmacia",
issn = "0014-8237",
publisher = "Romanian Society for Pharmaceutical Sciences",
number = "5",

}

TY - JOUR

T1 - Critical evaluation of modified-release formulation containing silybum marianum extract for oral application

AU - Sinka, Dávid

AU - Hagymási, Alexandra

AU - Fehér, Pálma

AU - Ujhelyi, Zoltán

AU - Vecsernyés, Miklós

AU - Fenyvesi, Ferenc

AU - Váradi, Judit

AU - Vasvári, Gábor

AU - Jurca, Tünde

AU - Nemeth, Sebastian

AU - Popa, Daniela Elena

AU - Bácskay, Ildikó

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Silymarin is the extract of active ingredients of the plant Silybum marianum. It is used in medicine for curing or preventing liver and gall diseases for thousands of years. Silymarin has a low solubility and permeability, belongs to BCS class IV. Its current pharmacotherapy means conventional dosage forms such as capsules, but it results in low bioavailability. Our main goals through the research were to formulate matrix tablets with silymarin as active ingredient. We used different carbopols as matrix-forming polymers. The complexation of silymarin with different β-cyclodextrins was intended to increase the solubility of the active ingredient. By achieving sustained release, our aim was to offer a better alternative than the conventional unsuccessful oral therapy. Comparing the results of our research, we could select the carbopol-cyclodextrin combination with the optimal drug release from the twenty different compounds. With these compositions, more than 85% of the silymarin was dissolved. The cytocompatibility of our product was proven, and the technology provided much better bioavailability than the conventional silymarin therapy.

AB - Silymarin is the extract of active ingredients of the plant Silybum marianum. It is used in medicine for curing or preventing liver and gall diseases for thousands of years. Silymarin has a low solubility and permeability, belongs to BCS class IV. Its current pharmacotherapy means conventional dosage forms such as capsules, but it results in low bioavailability. Our main goals through the research were to formulate matrix tablets with silymarin as active ingredient. We used different carbopols as matrix-forming polymers. The complexation of silymarin with different β-cyclodextrins was intended to increase the solubility of the active ingredient. By achieving sustained release, our aim was to offer a better alternative than the conventional unsuccessful oral therapy. Comparing the results of our research, we could select the carbopol-cyclodextrin combination with the optimal drug release from the twenty different compounds. With these compositions, more than 85% of the silymarin was dissolved. The cytocompatibility of our product was proven, and the technology provided much better bioavailability than the conventional silymarin therapy.

KW - Caco-2 cells

KW - Cyclodextrin

KW - HPBCD

KW - Modified-release

KW - Silybum marianum

UR - http://www.scopus.com/inward/record.url?scp=85073685900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073685900&partnerID=8YFLogxK

U2 - 10.31925/farmacia.2019.5.9

DO - 10.31925/farmacia.2019.5.9

M3 - Article

AN - SCOPUS:85073685900

VL - 67

SP - 806

EP - 819

JO - Farmacia

JF - Farmacia

SN - 0014-8237

IS - 5

ER -